1 / 50

Post-operative Radiotherapy for Esophageal Cancer

Post-operative Radiotherapy for Esophageal Cancer. Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007. Background. 5 year OS for locally advanced esophageal cancers (T3 or above, N+) is dismal. Preoperative ChemoRT vs. Post-operative ChemoRT.

anjolie-bradford
Download Presentation

Post-operative Radiotherapy for Esophageal Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007

  2. Background • 5 year OS for locally advanced esophageal cancers (T3 or above, N+) is dismal

  3. Preoperative ChemoRT vs. Post-operative ChemoRT • This has not been studied in a randomized trial head to head • Prefer pre-operative chemoRT • Allows for tumor downstaging  R0 resection • Complete pathologic response improves survival • Feasibility and Patient compliance • ? Earlier control of micro-metastatic disease • Only 1 of 6 randomized trials have shown OS benefit to neoadjuvant chemoRT (Walsh)

  4. Preoperative ChemoRT trials

  5. Post-operative RT+/- Chemotherapy • Data is primarily from Asia and Europe • Most randomized trials have looked at Surgery + RT vs. Surgery alone • No randomized trial has compared post-operative concurrent chemoRT to either chemotherapy or RT alone

  6. Indications for Post-operative RT • Standard Indications • Positive Margins • Gross Residual Disease • Less Clear • + LN • + ECE on adenopathy

  7. Current NCCN Guidelines for Post-operative Therapy

  8. Randomized Trials • Teniere et al Surg Gynecol Obstet. Aug 1991; 173(2): 123-30 (France) • S+ RT vs. S • Fok et al Surgery. Feb 1993; 113(2) 138-47 (Hong Kong) • S + RT vs. S • Xiao et al The Annals of Thoracic SurgeryFeb 2003; 75(2): 331-336 (China) • LN +  S+ RT vs. S • Macdonald et al NEJM. Sept 2001; 345:725-730 (USA) • GE junction  S + CRT vs. S

  9. French trial – Post-operative Radiation for Esophageal SCCA • 221 patients treated with “curative” resection • Squamous cell histology; mid/distal location • Post-op RT 45-55 Gy vs. Observation • Post-op RT did not improve OS • 5 y OS 19% (38% if node -; 7% if node + • Locoregional failure decreased after RT: 30 %  15% • Benefit significant in node negative patients: 35% LR failure vs. 10%

  10. Hong Kong Trial – Postoperative RT for Esophageal cancer • Single institution randomized trial, 130 patients • Curative Resection 60 patients  30 S+ RT vs. 30 S • Palliative Resection 70 patients  35 S + RT vs. 35 S • RT dose/technique unknown

  11. Hong Kong Trial - Results • Overall Median Survival, All patients • S + RT 8.7 months vs. S 15.2 months (p=0.02) • Local Recurrence, Palliative Surgery patients • S+ RT 20% vs. S 46 % (p=0.04) • Local Recurrence, Curative Surgery • S+RT 10% vs. S 13% • Complications • S+RT 37% vs. S 6% (p<0.0001) • Intra-thoracic recurrence, All patients • S+RT 4 patients vs. S 13 patients (p=0.01)

  12. Chinese trial – Post-operative radiation for Esophageal SCCA • Randomized to post-operative RT vs. observation; 495 patients  275 S, 220 S+ RT • Most of mid thoracic esophagus (67%), T3 (69%) and 48% had + LN • Margin status unknown

  13. Chinese Trial – RT parameters • RT • Extended Field RT • Included bilateral SCV, mediastinal and peri-gastric LN • 60 Gy

  14. Chinese Trial - Results • 5 y OS • S+ RT 41.3 % vs. S 37.1 % (p=0.45) • LN – • S+RT 52.8 % vs. S 51% (p=0.95) • LN+ • S+RT 29.2 % vs. S 14.7% (p=0.07) • Stage II • S+ RT 50.3 % vs. S 51.3 % (p=0.63) • Stage III OS • S+ RT 35.1% vs. S 13.1 % (p=0.003)

  15. Chinese trial - Results Stage III

  16. Chinese trial - Results LN + patients

  17. Chinese Trial - Sites of Failure

  18. Conclusions • Post-operative RT improves OS in Stage III and potentially LN + patients • Post-operative RT decreases risk of intra-thoracic LN recurrence and anastomotic recurrence

  19. Macdonald trial – Post-operative chemoRT for GE junction/stomach adenoCA • Randomized to post-operative chemoradiation vs. observation • 556 patients; 20% GE junction tumors • Stage IB – IV M0, negative margins • Adenocarcinoma histology • D2 dissection recommended • 10% D2; 36% D1; 54% D0

  20. Macdonald Trial - Treatment Schema • Chemotherapy  d 28 ChemoRT  2 cycles additional chemotherapy • Chemotherapy • 5FU + Leucovorin • RT – 45 Gy/25 fx • Tumor bed + Regional LN + 2 cm margin • 64% completed chemoRT as planned

  21. Macdonald Trial – Tumor Characteristics

  22. Macdonald Trial Results • 5 year Median Survival • S+ CRT 36 months vs. S 27 months • 3 y OS • S+ CRT 50% vs. S 41% (p= 0.005) • 3 y RFS • S + CRT 48% vs. S 31% (p <0.001)

  23. Macdonald Trial – Overall Survival

  24. Macdonald Trial – Relapse Free Survival

  25. Macdonald Trial – Sites of Relapse

  26. Macdonald Trial - Conclusions • Add chemoRT for GE junction adenoCA • T3 or higher • + LN • + margins, + residual disease • ? Selected T2 cases

  27. Non Randomized Trials • Liu HC et al. World J. Gastroenterology. 2005; 11(34): 5367-5372 • S+ CRT vs. S + RT • Bedard EL et al. CancerJun 2001; 91(12): 2423-2430 • N1 patients  S + CRT vs. S

  28. Taiwan Study – Postoperative ChemoRT vs. RT for esophageal SCCA • 60 patients; 30 patients in each arm • T3/T4 N0/N1 M0 thoracic esophageal SCCA • Surgery included • En-bloc esophagectomy – sub-total resection of esophagus with bilateral 10 cm adjacent soft-tissue margin • followed by proximal gastrectomy/porta hepatis LN dissection • Cervical LN sampling • Prospectively enrolled into post-operative chemoRT vs. RT alone

  29. Taiwan study – RT parameters • Treatment started within 3 weeks of surgery • RT • 40 Gy AP/PA followed by 15-20 Gy 3 D boost • standard 1.8 Gy/fx • Margins • Sup / Inf 5 cm • Elsewhere 3 cm • Mean dose 58.32 Gy (50.4 – 59.4 Gy)

  30. Taiwan study - Chemotherapy • Chemotherapy • 6 weekly cycles CDDP 30 mg/m2 during RT • 4 weeks after chemoRT, additional adjuvant chemotherapy 4 cycles of CDDP 20mg/m2 + 5 FU 1000mg/m2 X 5 days bolus infusion

  31. Taiwan study - Patient Characteristics

  32. Taiwan study - Patient Characteristics

  33. Taiwan Study - Results • ChemoRT • 30/30 received planned dose RT • 15/30 received planned dose concurrent chemo; 10 received 4/6 weekly cycles; 5 received <4 cycles • 15/30 received adjuvant chemotherapy • RT • 24/30 received planned dose RT • Median follow-up 18 months

  34. Taiwan Study - Results • ChemoRT • Mean survival 31.9 months • 3 y/o OS 70% • 3 y/o LRF 40% • 3 y/o DF 27% • RT • Mean survival 20.7 months • 3 y/o OS 33.7% • 3 y/o LRF 60% • 3 y/o DF 57% • Treatment modality and tumor grade were significant on multi-variate analysis

  35. Taiwan Study - Results

  36. Taiwan Study - Results

  37. Taiwan Study - ChemoRT complications • Complications • Anastomotic Stricture 36% • Chronic Aspiration 33% • Pneumonia 20%

  38. Taiwan Study - Conclusions • ChemoRT showed improved OS compared to RT alone in T3 or higher patients • Improved overall survival compared to historical data for surgery alone

  39. Canadian Study – Postoperative chemoRT in patients with N+ esophageal cancer • Retrospective review of N1 patients – chemo RT vs. surgery alone; 70 patients • 39 pts to chemoRT arm vs. 31 patients to surgery alone; in final analysis 38 pts. ChemoRT & 28 pts. Surgery alone • Thoracic & GE junction tumors • AdenoCA & Squamous histology • T1-T4, all N1 • Transhiatal esophagectomy

  40. Canadian Study - Treatment Schema • 2 cycles of chemotherapy  RT with 3rd & 4th cycle of chemotherapy • Chemotherapy • CDDP 60 mg/m2 • Continuous infusion 5-FU • Epirubicin 50 mg/m2 in last 6 patients • RT • 50 Gy (36 Gy AP/PA followed by 14 Gy 3D planning)

  41. Canadian Study - Patient Characteristics • Patient characteristics and tumor characteristics well balanced between two groups • No data on # LN + or ECE status provided

  42. Canadian Study –Tumor Characteristics

  43. Canadian Study - Results • Median follow-up 19 months • Surgery + ChemoRT • Median DFS – 10.2 months • Local Recurrence 13% • Median Time to LR 22.2 months • Median OS 47.5 months • 5 y OS 48% • Surgery • Median DFS – 10.6 months • Local Recurrence 35% • Median Time to LR 9.5 months • Median OS 14.1 months • 5 y OS 0%

  44. Canadian Study – Overall Survival

  45. Canadian Trial - Conclusion • Benefit of ChemoRT in node + patients

  46. Additional abstracts • Kurtzman SM et al. (ASTRO 1995) • 192 patients • Esophageal adenoCA • Post-op RT with 5FU/Leucovorin & γ-Interferon • 39% 3 y OS

  47. Additional abstracts • Kang HJ et al (ASCO 1992) • Phase 2 trial • ChemoRT • 40-50 Gy • CDDP + 5 FU • 47% 20 month survival rate • 93% LCR

  48. What about post-op chemotherapy alone? • 2 randomized Japanese trials • Ando N et al. J of Thoracic and Cardiovascular Surgery. 1997; 114;204-205 • Randomized study; 205 patients • S + C vs. S alone • Chemo – 2 cycles of Cisplatin (70 mg./m2) + Vindesine • 5 y OS S + C 48.1 % vs. S 44.9% (p = NS) • Ando N et al. JCO. Dec 2003; 21(24): 4592-4596 • Randomized study; 242 patients • Thoracic SCCA • S+C vs. S alone • Chemo – 2 cycles of Cisplatin (80 mg/m2) + 5 FU (800mg/m2/5 day infusion) • 5 y OS 61 vs. 52 % (p=0.13);5 y DFS 55% vs. 45% (p=0.04); 5 y DFS in N + patients 52% vs. 38% (p=0.04) • Significant nodal failure in S + C patients; role of RT??

  49. Overall Conclusions • Treatment decisions need to be individualized • Pre-operative chemoRT preferable when needed • Recognize the morbidity of neoadjuvant chemoRT; consider surgery first in resectable patients with marginal performance status • Post-operative chemoRT for • + margins, residual gross disease • + LN • locally advanced disease (T3 or higher) with – margins, - LN?

  50. Acknowledgements • Dr. John Holland • Dr. Charles Thomas • Dr. Tasha Mcdonald

More Related